François Sevrin

is a Pediatric Oncology Consultant at the Oscar Lambret Center. He completed his medical studies and pediatric residency at Lille University Hospital (Lille, France). He specialized in pediatric oncology, undertaking an inter-hospital rotation at Gustave Roussy (Villejuif, France) and a clinical fellowship at the Oscar Lambret Center (Lille, France) before joining the Pediatric Drug Development Team at The Royal Marsden (Sutton, UK) for a one-year clinical research fellowship.
He now leads the Pediatric, Adolescent, and Young Adult Oncology Drug Development Program at the Oscar Lambret Center, focusing on oncology drug development and experimental therapeutics for high-risk, poor-prognosis malignancies, particularly solid tumors and neuro-oncology.
He is currently pursuing a PhD in proteomics at PRISM (Proteomic, Inflammatory Response, Mass Spectrometry) Inserm U1192 (Lille, France), focusing on rhabdomyosarcoma and immunotherapy, further advancing his expertise in pediatric sarcomas and novel therapeutic approaches.
Dr. Sevrin is a member of the New Drug Committee of the French Society of Pediatric Oncology (SFCE) and the European Paediatric Soft Tissue Sarcoma Group (EPSSG). The Oscar Lambret Center is also part of the Innovative Therapies for Children with Cancer (ITCC) European Early Phase Trials Consortium and is one of the eight CLIP2-designated pediatric centers in France specializing in early phase clinical trials.